Hepatic safety profile of darunavir with low-dose ritonavir (DRV/r) in HIV/HCV coinfected and HIV monoinfected patients.
Giulia Morsica(Vita-Salute San Raffaele University), Caterina Uberti‐Foppa(Vita-Salute San Raffaele University), Giampaolo Bianchi(Azienda Ospedaliero-Universitaria di Modena), Stefania Salpietro(IRCCS Ospedale San Raffaele), Sabrina Bagaglio(Vita-Salute San Raffaele University), Camilla Conte, L. Porrino(San Raffaele University of Rome)
PubMed
July 1, 2011
Cited by 8
Related Papers
Hepatitis C viraemia and liver disease in symptom-free individuals with anti-HCV
|The Lancet|1992|393
Dietary treatment of urinary risk factors for renal stone formation. A review of CLU Working Group
|Archivio Italiano di Urologia e Andrologia|2015|202
Human Papillomavirus Infection and Associated Cervical Disease in Human Immunodeficiency Virus–Infected Women: Effect of Highly Active Antiretroviral Therapy
|The Journal of Infectious Diseases|2001|173
Discontinuation of Secondary Prophylaxis against<i>Pneumocystis carinii</i>Pneumonia in Patients with HIV Infection Who Have a Response to Antiretroviral Therapy
|New England Journal of Medicine|2001|168